[96a5a0]: / output / allTrials / identified / NCT01940172_identified.json

Download this file

926 lines (926 with data), 41.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
{
"info": {
"nct_id": "NCT01940172",
"official_title": "A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "Inclusion Criteria-If subject:\n\n* Is a women who is at least 18 years of age.\n* Has a negative serum pregnancy test at screening for women of childbearing potential.\n* Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) may have had a maximum of 3 prior systemic chemotherapy regimens (excluding hormonal therapies and investigational agents).\n* Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale.\n* Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.\n* Has a life expectancy of at least 3 months.\n* Has adequate liver, renal, pancreatic, coagulation and bone marrow function.\n\nExclusion Criteria-If subject:\n\n* Has symptomatic or uncontrolled brain metastases requiring current treatment (<8 weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).\n* Has known intolerance to any of the study drugs or any of their excipients.\n* Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C.\n* Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without medication, or not controlled despite medications.\n* Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor necrosis factor (TNF) therapies, experimental or approved anticancer proteins/antibodies therapy\n\n ≤28 days before enrollment.\n* Has impaired cardiac function or clinically significant cardiac disease including the following:\n\n 1. New York Heart Association Grade III or IV congestive heart failure.\n 2. Myocardial infarction within the last 12 months prior to dosing with birinapant.\n* Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on medication). Subjects with a ventricular pacemaker for whom QT interval is not measurable may be eligible.\n* Has a lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.\n* Has any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.\n* Has a prior history of cranial nerve palsy.\n* Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.\n* Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine histology, clear cell or mucinous histology or subjects with borderline ovarian cancer.\n* Requires concomitant chronic use of anti-TNF therapies, corticosteroids or nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed."
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Is a women who is at least 18 years of age.",
"criterions": [
{
"exact_snippets": "women",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected gender",
"expected_value": "female"
}
]
},
{
"exact_snippets": "at least 18 years of age",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* Has a negative serum pregnancy test at screening for women of childbearing potential.",
"criterions": [
{
"exact_snippets": "negative serum pregnancy test",
"criterion": "serum pregnancy test",
"requirements": [
{
"requirement_type": "result",
"expected_value": "negative"
}
]
},
{
"exact_snippets": "women of childbearing potential",
"criterion": "childbearing potential",
"requirements": [
{
"requirement_type": "status",
"expected_value": "women of childbearing potential"
}
]
}
]
},
{
"line": "* Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) may have had a maximum of 3 prior systemic chemotherapy regimens (excluding hormonal therapies and investigational agents).",
"criterions": [
{
"exact_snippets": "Pathologically confirmed ovarian cancer (epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer)",
"criterion": "ovarian cancer type",
"requirements": [
{
"requirement_type": "confirmation",
"expected_value": "pathologically confirmed"
},
{
"requirement_type": "subtypes",
"expected_value": [
"epithelial ovarian cancer",
"primary peritoneal cancer",
"fallopian tube cancer"
]
}
]
},
{
"exact_snippets": "may have had a maximum of 3 prior systemic chemotherapy regimens",
"criterion": "prior systemic chemotherapy regimens",
"requirements": [
{
"requirement_type": "maximum number",
"expected_value": {
"operator": "<=",
"value": 3,
"unit": "regimens"
}
}
]
},
{
"exact_snippets": "excluding hormonal therapies and investigational agents",
"criterion": "prior treatments",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": [
"hormonal therapies",
"investigational agents"
]
}
]
}
]
},
{
"line": "* Has a performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale.",
"criterions": [
{
"exact_snippets": "performance status of 0 or 1 by the Eastern Cooperative Oncology Group (ECOG) scale",
"criterion": "performance status",
"requirements": [
{
"requirement_type": "scale",
"expected_value": "Eastern Cooperative Oncology Group (ECOG)"
},
{
"requirement_type": "value",
"expected_value": [
"0",
"1"
]
}
]
}
]
},
{
"line": "* Has a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria AND meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria.",
"criterions": [
{
"exact_snippets": "measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria",
"criterion": "measurable disease",
"requirements": [
{
"requirement_type": "criteria",
"expected_value": "Response Evaluation Criteria in Solid Tumors (RECIST) 1.1"
}
]
},
{
"exact_snippets": "meet Gynecologic Cancer InterGroup (GCIG) CA 125 criteria",
"criterion": "CA 125 criteria",
"requirements": [
{
"requirement_type": "criteria",
"expected_value": "Gynecologic Cancer InterGroup (GCIG)"
}
]
}
]
},
{
"line": "* Has a life expectancy of at least 3 months.",
"criterions": [
{
"exact_snippets": "life expectancy of at least 3 months",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
]
}
]
},
{
"line": "* Has adequate liver, renal, pancreatic, coagulation and bone marrow function.",
"criterions": [
{
"exact_snippets": "adequate liver ... function",
"criterion": "liver function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... renal ... function",
"criterion": "renal function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... pancreatic ... function",
"criterion": "pancreatic function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... coagulation ... function",
"criterion": "coagulation function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "adequate ... bone marrow function",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "* Has symptomatic or uncontrolled brain metastases requiring current treatment (<8 weeks from last cranial radiation treatment or <4 weeks from last steroid treatment).",
"criterions": [
{
"exact_snippets": "Has symptomatic or uncontrolled brain metastases",
"criterion": "brain metastases",
"requirements": [
{
"requirement_type": "symptomatic",
"expected_value": true
},
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "requiring current treatment",
"criterion": "brain metastases treatment",
"requirements": [
{
"requirement_type": "current",
"expected_value": true
}
]
},
{
"exact_snippets": "<8 weeks from last cranial radiation treatment",
"criterion": "time since last cranial radiation treatment",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": "<",
"value": 8,
"unit": "weeks"
}
}
]
},
{
"exact_snippets": "<4 weeks from last steroid treatment",
"criterion": "time since last steroid treatment",
"requirements": [
{
"requirement_type": "time since",
"expected_value": {
"operator": "<",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* Has known intolerance to any of the study drugs or any of their excipients.",
"criterions": [
{
"exact_snippets": "known intolerance to any of the study drugs",
"criterion": "intolerance to study drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "known intolerance to ... any of their excipients",
"criterion": "intolerance to excipients of study drugs",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has uncontrolled hypertension defined as blood pressure >160/100 mmHg without medication, or not controlled despite medications.",
"criterions": [
{
"exact_snippets": "uncontrolled hypertension",
"criterion": "hypertension",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
},
{
"exact_snippets": "blood pressure >160/100 mmHg",
"criterion": "blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 160,
"unit": "mmHg"
}
}
]
},
{
"exact_snippets": "blood pressure >160/100 mmHg",
"criterion": "blood pressure",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">",
"value": 100,
"unit": "mmHg"
}
}
]
},
{
"exact_snippets": "without medication",
"criterion": "medication for hypertension",
"requirements": [
{
"requirement_type": "use",
"expected_value": false
}
]
},
{
"exact_snippets": "not controlled despite medications",
"criterion": "hypertension control with medication",
"requirements": [
{
"requirement_type": "control",
"expected_value": false
}
]
}
]
},
{
"line": "* Has received systemic chemotherapy, hormonal therapy, immunotherapy, anti-tumor necrosis factor (TNF) therapies, experimental or approved anticancer proteins/antibodies therapy",
"criterions": [
{
"exact_snippets": "Has received systemic chemotherapy",
"criterion": "systemic chemotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... hormonal therapy",
"criterion": "hormonal therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... immunotherapy",
"criterion": "immunotherapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... anti-tumor necrosis factor (TNF) therapies",
"criterion": "anti-tumor necrosis factor (TNF) therapies",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
},
{
"exact_snippets": "Has received ... experimental or approved anticancer proteins/antibodies therapy",
"criterion": "experimental or approved anticancer proteins/antibodies therapy",
"requirements": [
{
"requirement_type": "receipt",
"expected_value": true
}
]
}
]
},
{
"line": "≤28 days before enrollment.",
"criterions": [
{
"exact_snippets": "≤28 days before enrollment",
"criterion": "time before enrollment",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 28,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Has impaired cardiac function or clinically significant cardiac disease including the following:",
"criterions": [
{
"exact_snippets": "impaired cardiac function",
"criterion": "cardiac function",
"requirements": [
{
"requirement_type": "impairment",
"expected_value": true
}
]
},
{
"exact_snippets": "clinically significant cardiac disease",
"criterion": "cardiac disease",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
}
]
},
{
"line": "1. New York Heart Association Grade III or IV congestive heart failure.",
"criterions": [
{
"exact_snippets": "New York Heart Association Grade III or IV congestive heart failure.",
"criterion": "New York Heart Association Grade",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"III",
"IV"
]
}
]
},
{
"exact_snippets": "New York Heart Association Grade III or IV congestive heart failure.",
"criterion": "congestive heart failure",
"requirements": [
{
"requirement_type": "severity",
"expected_value": [
"III",
"IV"
]
}
]
}
]
},
{
"line": "2. Myocardial infarction within the last 12 months prior to dosing with birinapant.",
"criterions": [
{
"exact_snippets": "Myocardial infarction within the last 12 months",
"criterion": "myocardial infarction",
"requirements": [
{
"requirement_type": "time frame",
"expected_value": {
"comparisons": [
{
"operator": "<=",
"value": 12,
"unit": "months"
}
]
}
}
]
}
]
},
{
"line": "* Has a QT interval corrected for heart rate (QTcB) >480 msec (including subjects on medication). Subjects with a ventricular pacemaker for whom QT interval is not measurable may be eligible.",
"criterions": [
{
"exact_snippets": "QT interval corrected for heart rate (QTcB) >480 msec",
"criterion": "QT interval corrected for heart rate (QTcB)",
"requirements": [
{
"requirement_type": "length",
"expected_value": {
"operator": ">",
"value": 480,
"unit": "msec"
}
}
]
},
{
"exact_snippets": "ventricular pacemaker",
"criterion": "ventricular pacemaker",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has a lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03) (except alopecia) due to therapy administered prior to the initiation of study drug dosing.",
"criterions": [
{
"exact_snippets": "lack of recovery of prior adverse non-hematological events to Grade ≤1 severity (National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v4.03)",
"criterion": "recovery of prior adverse non-hematological events",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<=",
"value": 1,
"unit": "Grade (NCI CTCAE v4.03)"
}
}
]
}
]
},
{
"line": "* Has any concurrent disease and/or medical condition that, in the opinion of the Investigator, would prevent the subject's participation, render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen), or limit the subject's compliance with the protocol's required evaluations.",
"criterions": [
{
"exact_snippets": "Has any concurrent disease and/or medical condition",
"criterion": "concurrent disease and/or medical condition",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "in the opinion of the Investigator, would prevent the subject's participation",
"criterion": "investigator's opinion on participation",
"requirements": [
{
"requirement_type": "opinion",
"expected_value": "would not prevent participation"
}
]
},
{
"exact_snippets": "render the subject at excessive risk (including excessive risks due to the toxicity profile of the planned combination chemotherapeutic regimen)",
"criterion": "excessive risk",
"requirements": [
{
"requirement_type": "risk level",
"expected_value": "not excessive"
}
]
},
{
"exact_snippets": "limit the subject's compliance with the protocol's required evaluations",
"criterion": "compliance with protocol's required evaluations",
"requirements": [
{
"requirement_type": "compliance",
"expected_value": "not limited"
}
]
}
]
},
{
"line": "* Has a prior history of cranial nerve palsy.",
"criterions": [
{
"exact_snippets": "prior history of cranial nerve palsy",
"criterion": "cranial nerve palsy",
"requirements": [
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Has autoimmune diseases or inflammatory diseases, for example, active rheumatoid arthritis, active inflammatory bowel disease or any chronic inflammatory conditions.",
"criterions": [
{
"exact_snippets": "Has autoimmune diseases",
"criterion": "autoimmune diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "inflammatory diseases",
"criterion": "inflammatory diseases",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "active rheumatoid arthritis",
"criterion": "rheumatoid arthritis",
"requirements": [
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "active inflammatory bowel disease",
"criterion": "inflammatory bowel disease",
"requirements": [
{
"requirement_type": "activity status",
"expected_value": "active"
}
]
},
{
"exact_snippets": "chronic inflammatory conditions",
"criterion": "chronic inflammatory conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* Has pseudomyxoma, mesothelioma, unknown primary tumor, sarcoma, neuroendocrine histology, clear cell or mucinous histology or subjects with borderline ovarian cancer.",
"criterions": [
{
"exact_snippets": "Has pseudomyxoma",
"criterion": "pseudomyxoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "mesothelioma",
"criterion": "mesothelioma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "unknown primary tumor",
"criterion": "unknown primary tumor",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sarcoma",
"criterion": "sarcoma",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "neuroendocrine histology",
"criterion": "neuroendocrine histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clear cell or mucinous histology",
"criterion": "clear cell histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "clear cell or mucinous histology",
"criterion": "mucinous histology",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "borderline ovarian cancer",
"criterion": "borderline ovarian cancer",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Inclusion Criteria-If subject:",
"criterions": []
},
{
"line": "Exclusion Criteria-If subject:",
"criterions": []
},
{
"line": "* Has known or suspected diagnosis of human immunodeficiency virus (HIV) or chronic active Hepatitis B or C.",
"criterions": [
{
"exact_snippets": "known or suspected diagnosis of human immunodeficiency virus (HIV)",
"criterion": "human immunodeficiency virus (HIV)",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
},
{
"exact_snippets": "known or suspected diagnosis of ... chronic active Hepatitis B",
"criterion": "chronic active Hepatitis B",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
},
{
"exact_snippets": "known or suspected diagnosis of ... chronic active Hepatitis C",
"criterion": "chronic active Hepatitis C",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": "known or suspected"
}
]
}
]
},
{
"line": "* Requires concomitant chronic use of anti-TNF therapies, corticosteroids or nonsteroidal anti- inflammatory drugs (NSAIDS). Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed.",
"criterions": [
{
"exact_snippets": "Requires concomitant chronic use of anti-TNF therapies",
"criterion": "anti-TNF therapies",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Requires concomitant chronic use of ... corticosteroids",
"criterion": "corticosteroids",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Requires concomitant chronic use of ... nonsteroidal anti-inflammatory drugs (NSAIDS)",
"criterion": "nonsteroidal anti-inflammatory drugs (NSAIDS)",
"requirements": [
{
"requirement_type": "use",
"expected_value": "chronic"
}
]
},
{
"exact_snippets": "Intermittent use (7 or fewer days per 14 days) of corticosteroids as pre-medications is allowed",
"criterion": "corticosteroids",
"requirements": [
{
"requirement_type": "use",
"expected_value": "intermittent (7 or fewer days per 14 days)"
}
]
}
]
}
]
}